文献速递系统性红斑狼疮

贝利尤单抗治疗系统性红斑狼疮的长期安全性与有限器官损伤:III期研究扩展研究

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究为BLISS-52和BLISS-76的长期扩展研究,纳入738例SLE患者接受贝利尤单抗静脉注射联合标准治疗。结果显示不良事件年发生率稳定或下降,严重及重度不良事件未增加,平均SLICC/ACR损伤指数评分自基线0.6(1.02)保持稳定,第8年87.7%(57/65)患者损伤指数无变化,表明长期安全性良好且器官损伤进展极小。

要点

  • 贝利尤单抗长期安全性稳定,无新安全信号,不良事件年发生率稳定或下降。
  • 平均SLICC/ACR损伤指数自基线0.6(1.02)保持稳定,第8年87.7%患者无变化。

核心结论

  • 贝利尤单抗在SLE患者中显示稳定的安全性特征,无新安全信号,8年间器官损伤进展极小。

研究设计与样本

  • 多中心长期扩展研究(GlaxoSmithKline Study BEL112234),纳入BLISS-52和BLISS-76的非美国SLE患者,接受贝利尤单抗静脉注射每4周联合标准治疗。

主要发现

  • 738例患者进入扩展研究,735/738(99.6%)接受至少一剂贝利尤单抗。
  • 不良事件包括严重和重度不良事件的年发生率随时间保持稳定或下降。
  • 实验室参数总体保持稳定。
  • 平均(标准差)SLICC/ACR损伤指数评分在基线(首次贝利尤单抗剂量前)为0.6(1.02)并保持稳定;第8年57/65(87.7%)患者损伤指数较基线无变化。

关键数值与推荐

  • SLICC/ACR损伤指数每48周评估一次。
  • 研究持续至贝利尤单抗商业可及,随后8周随访期。

临床怎么用

  • 支持贝利尤单抗在SLE患者中的长期使用,需监测不良事件及器官损伤,但长期器官损伤累积风险低。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This extension study of the Phase III, randomized, placebo-controlled Belimumab International SLE Study (BLISS)-52 and BLISS-76 studies allowed non-US patients with SLE to continue belimumab treatment, in order to evaluate its long-term safety and tolerability including organ damage accrual. METHODS: In this multicentre, long-term extension study (GlaxoSmithKline Study BEL112234) patients received i.v. belimumab every 4 weeks plus standard therapy. Adverse events (AEs) were assessed monthly and safety-associated laboratory parameters were assessed at regular intervals. Organ damage (SLICC/ACR Damage Index) was assessed every 48 weeks. The study continued until belimumab was commercially available, with a subsequent 8-week follow-up period. RESULTS: A total of 738 patients entered the extension study and 735/738 (99.6%) received one or more doses of belimumab. Annual incidence of AEs, including serious and severe AEs, remained stable or declined over time. Sixty-nine (9.4%) patients experienced an AE resulting in discontinuation of belimumab or withdrawal from the study. Eleven deaths occurred (and two during post-treatment follow-up), including one (cardiogenic shock) considered possibly related to belimumab. Laboratory parameters generally remained stable. The mean (s.d.) SLICC/ACR Damage Index score was 0.6 (1.02) at baseline (prior to the first dose of belimumab) and remained stable. At study year 8, 57/65 (87.7%) patients had no change in SLICC/ACR Damage Index score from baseline, indicating low organ damage accrual. CONCLUSION: Belimumab displayed a stable safety profile with no new safety signals. There was minimal organ damage progression over 8 years. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00424476 (BLISS-52), NCT00410384 (BLISS-76), NCT00732940 (BEL112232), NCT00712933 (BEL112234).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. van Vollenhoven RF, Navarra SV, Levy RA, et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology (Oxford). 2020. PMID: 31302695. doi:10.1093/rheumatology/kez279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。